AIBT.US Aibotics Inc.
- Market cap
- USD 2.76M
- P/E
- 0.3x
- P/B
- 11.76x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AIBT.US undervalued?
Graham numberAIBT.US trades 59.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aibotics Inc. fundamental analysis
No fundamental analysis for Aibotics Inc. yet.
Aibotics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aibotics Inc.
Aibotics Inc., together with its subsidiaries, engages in the study of psychedelics for the treatment of mental health issues in the United States. It provides psychedelic-enhanced holistic methodologies for the treatment of palliative care, depression, and anxiety. The company was formerly known as Mycotopia Therapies, Inc. and changed its name to Aibotics Inc. in February 2025. Aibotics Inc. is based in Miami, Florida.
Full company profileAibotics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aibotics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 12.8M | 14.9M | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.18K | 0.00 |
| Gross Profit | 284K | 350K | -672.00 | -323.00 | 0.00 | -248.00 | -1.00K | -61.2K | -668K | -665K | -661K |
| Operating Income | 90.0K | 175K | -186K | -252K | -14.2K | -4.99M | -1.74M | -617K | -1.63M | -1.84M | -1.55M |
| EBITDA | 111K | 206K | -169K | -253K | -13.7K | -4.99M | -1.74M | -556K | -966K | -1.18M | -885K |
| Net Income | 72.4K | 130K | 61.2K | 4.80K | -16.0K | -5.14M | -2.61M | -1.18M | -1.85M | -2.22M | -1.91M |
| EPS | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | -0.38 | -0.18 | -0.08 | -0.14 | -0.01 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.19M | 1.48M | 1.50M | 1.22M | 111K | 1.27M | 387K | 2.22M | 1.46M | 875K | 550K |
| Total Liabilities | 744K | 909K | 853K | 563K | 127K | 1.22M | 1.28M | 4.25M | 4.85M | 4.83M | 5.15M |
| Shareholders' Equity | 442K | 572K | 647K | 652K | 454K | 52.0K | -891K | -2.03M | -3.39M | -3.96M | -4.60M |
| Cash & Short-term Investments | 442K | 680K | - | 209K | 111K | 1.27M | 386K | 279K | 185K | 256K | 233K |
| Total Debt | - | - | - | - | 125K | 749K | 655K | 1.09M | 1.27M | 1.28M | 165K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 93.7K | 233K | -68.5K | 98.7K | -303K | -235K | -657K | -107K | -259K | -458K | -167K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 2.75K | 0.00 | 2.75K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 93.7K | 233K | -68.5K | 98.7K | -303K | -238K | -657K | -107K | -259K | -458K | -167K |
| Ratios | |||||||||||
| ROE | 16.4% | 22.7% | 9.5% | 0.7% | -3.5% | -9,877.9% | - | - | - | - | - |
| ROA | 6.1% | 8.8% | 4.1% | 0.4% | -14.5% | -404.6% | -674.2% | -53.2% | -126.9% | -253.3% | -347.6% |
| Net Profit Margin | 0.6% | 0.9% | - | - | - | - | - | - | - | -101,500.3% | - |
| Debt to Equity | - | - | - | - | 0.28x | 14.39x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aibotics Inc. dividends
Aibotics Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on May 1, 2014.
Who owns Aibotics Inc.
- Insiders 28.46%
- Institutions 0.00%
- Public & others 71.54%
- Shares outstanding 890M
- Free float 597M
Aibotics Inc. company profile
- Company name
- Aibotics Inc.
- Ticker
- AIBT.US
- Exchange
- USA Stocks
- Sector
- Consumer Cyclical
- Industry
- Leisure
- Fiscal year end
- December
- Address
- 100 SE 2nd Street, Miami, FL, United States, 33131
- Phone
- 954 233 3511
- Website
- aibotics.ai
About Aibotics Inc.
Aibotics Inc., together with its subsidiaries, engages in the study of psychedelics for the treatment of mental health issues in the United States. It provides psychedelic-enhanced holistic methodologies for the treatment of palliative care, depression, and anxiety. The company was formerly known as Mycotopia Therapies, Inc. and changed its name to Aibotics Inc. in February 2025. Aibotics Inc. is based in Miami, Florida.
Aibotics Inc. management
1- Mr. Benjamin KaplanChairman, Chief Executive and Financial Officer & President · born 1968